<DOC>
	<DOCNO>NCT02748616</DOCNO>
	<brief_summary>In vitro finding establish ursodeoxycholic acid surrogate deoxycholic acid prevent growth C. difficile , interrupt recurrence . Investigators administer ursodeoxycholic acid two month , begin Metronidazole and/or Vancomycin ( 8 10 day ) , antibiotic currently use treatment acute C.Difficile infection . Ursodeoxycholic acid prevents c.difficile recurrence ( ) directly suppress growth C. Difficile ( b ) permit restoration normal fecal bile acid composition ( 80 % deoxycholic acid ) maintain growth suppression .</brief_summary>
	<brief_title>C. Difficile Ursodiol</brief_title>
	<detailed_description>The non-investigational reference therapy , Metronidazole , Vancomycin fidaxomicin , FDA-approved antibiotic currently use today effectiveness suppress growth C. difficile therefore quickly eliminate colitis diarrhea . However , promote restoration normal bacterial flora . Therefore , medication stop , C. difficile colitis return . In vitro finding establish ursodeoxycholic acid surrogate deoxycholic acid prevent growth C. difficile , interrupt recurrence .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Male female patient recurrent C. difficile colitis 21 year age old Capable give informed consent Patients gastrointestinal problem prone cause diarrhea control period study . Lactose intolerance gluten enteropathy exclusion provide potential subject asymptomatic expect adhere appropriate dietary regimen . Patients contraindication metronidazole vancomycin and/or ursodiol tablet component formulation . Patients available longterm followup ( 2 month ) physician exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Colitis</keyword>
	<keyword>Bile</keyword>
</DOC>